Biotech Candidates

Update

Biotech Candidates

Biotech Candidates — March 26, 2026

Overview

Biotech stabilizing at the margins. LLY remains the key oversold watch — still approaching entry at RSI 31.8, barely holding above SMA200 (+0.4%). MRNA upgraded to strong-up territory with RSI 57. BIIB quietly strong-up (+21% vs SMA200). CRSP continues to deteriorate — death cross, -15% below SMA200, down -20.9% in 30D. TMO showing signs of life with a +6.9% week. Gene editing sector (CRSP, NTLA) diverging sharply.

Candidates

Ticker Price RSI Trend 7D 30D Signal Take
LLY $896.61 31.8 weak-down +0.4% -14.8% GC GLP-1 giant. Near oversold, barely above SMA200. Entry zone forming.
MRNA $53.57 57.3 strong-up +2.7% 0.0% GC mRNA platform strong-up. +62% vs SMA200. Momentum intact.
BIIB $191.06 56.8 strong-up +3.4% -0.4% GC Quietly strong. +21% vs SMA200. Under-the-radar.
TMO $488.85 44.0 down +6.9% -6.1% GC Life sciences tools bouncing. -5.2% vs SMA200, watch for reversal.
VRTX $453.74 43.9 weak-down +1.2% -8.7% GC Pain franchise holding above SMA200 (+3.4%). Stable.
NTLA $13.24 51.6 strong-up +4.7% -3.9% GC In-vivo gene editing momentum intact. +4.4% vs SMA200.
CRSP $47.55 41.1 strong-down +0.9% -20.9% DC Gene editing broken. Death cross, -15.2% below SMA200. Avoid.

Action Items

  • LLY: Watch RSI 30 for staged entry. Still above SMA200 — the last line of support.
  • MRNA: Hold. Strong-up trend with golden cross. Don't sell momentum.
  • BIIB: Underappreciated setup. Watch for breakout confirmation.
  • TMO: +6.9% week — watch for follow-through above SMA200 ($516).
  • CRSP: Avoid. Death cross + -20.9% 30D = no floor in sight.
10 events
DateTypeEvent
Mar 26 ScanBiotech Scan Mar 24 ScanBiotech Scan Mar 31 UpdateBiotech Candidates Mar 31 ScanBiotech Scan Mar 20 ScanBiotech Scan Mar 13 ScanBiotech Scan Mar 12 UpdateBiotech Mar 12 ScanBiotech Scan Mar 11 ScanBiotech Scan Mar 10 ScanBiotech Scan

No direct external sources are attached to this read.